Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 5/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.35 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21605876 | 1.00 | MCHR1 (0.36) | MCHR1GRM5FEN1ALOX5APGHSR | |
| SCHEMBL21605881 | 1.00 | MCHR1 (0.36) | MCHR1GRM5FEN1ALOX5APGHSR | |
| SCHEMBL23871278 | 0.88 | OGA (0.38) | GRM5FEN1ALOX5APGHSROGA | |
| SCHEMBL21605950 | 0.88 | OGA (0.38) | GRM5FEN1ALOX5APGHSROGA | |
| SCHEMBL21605949 | 0.88 | OGA (0.38) | GRM5FEN1ALOX5APGHSROGA | |
| SCHEMBL21605880 | 0.86 | OGA (0.37) | GRM5FEN1ALOX5APOGA | |
| SCHEMBL21605832 | 0.83 | ALOX5AP (0.37) | GRM5FEN1ALOX5APOGA | |
| SCHEMBL21605959 | 0.83 | ALOX5AP (0.37) | GRM5FEN1ALOX5APOGA | |
| SCHEMBL21603364 | 0.82 | GRM5 (0.35) | GRM5FEN1ALOX5APOGA | |
| SCHEMBL21603309 | 0.82 | GRM5 (0.35) | GRM5FEN1ALOX5APOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | MCHR1 4744/4885GRM5 887/4885FEN1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.